Pericyte PDGFR-Beta Agonist for Neurovascular Rescue
📖 Wiki Page
idea1751 wordssynced 2026-04-02
Pericyte PDGFR-β Agonist for Neurovascular Rescue
Overview
This therapeutic strategy targets pericyte survival and function through PDGFR-β signaling agonism to restore blood-brain barrier integrity in early neurodegeneration. Pericyte loss is among the earliest detectable pathologies in Alzheimer's disease — preceding amyloid deposition, tau pathology, and neuronal loss — yet no clinical program targets pericyte preservation. PDGF-BB/PDGFR-β signaling is the master regulator of pericyte recruitment, survival, and contractile function. A pericyte-protective strategy could prevent BBB breakdown, reduce neuroinflammation by blocking peripheral immune infiltration, and paradoxically improve drug delivery by maintaining organized transcytosis pathways.[@sweeney2018][@bell2010]
Expression: PDGFR-β is highly expressed on brain pericytes, with lower expression on vascular smooth muscle cells and fibroblasts
Localization: Abluminal surface of brain capillaries; pericytes ensheath >80% of the cerebrovascular endothelium
Mechanistic Rationale
The neurovascular unit depends critically on pericytes for BBB integrity, cerebral blood flow regulation, and neurovascular coupling. Pericyte dysfunction and pericyte loss drive a vicious cycle in neurodegeneration:[@sweeney2018]
...
Pericyte PDGFR-β Agonist for Neurovascular Rescue
Overview
This therapeutic strategy targets pericyte survival and function through PDGFR-β signaling agonism to restore blood-brain barrier integrity in early neurodegeneration. Pericyte loss is among the earliest detectable pathologies in Alzheimer's disease — preceding amyloid deposition, tau pathology, and neuronal loss — yet no clinical program targets pericyte preservation. PDGF-BB/PDGFR-β signaling is the master regulator of pericyte recruitment, survival, and contractile function. A pericyte-protective strategy could prevent BBB breakdown, reduce neuroinflammation by blocking peripheral immune infiltration, and paradoxically improve drug delivery by maintaining organized transcytosis pathways.[@sweeney2018][@bell2010]
Expression: PDGFR-β is highly expressed on brain pericytes, with lower expression on vascular smooth muscle cells and fibroblasts
Localization: Abluminal surface of brain capillaries; pericytes ensheath >80% of the cerebrovascular endothelium
Mechanistic Rationale
The neurovascular unit depends critically on pericytes for BBB integrity, cerebral blood flow regulation, and neurovascular coupling. Pericyte dysfunction and pericyte loss drive a vicious cycle in neurodegeneration:[@sweeney2018]
BBB breakdown: Pericyte loss increases paracellular permeability, allowing plasma proteins (fibrinogen, thrombin, albumin) into the brain parenchyma[@bell2010]
Impaired Aβ clearance: Pericytes clear Aβ via LRP1-mediated transcytosis; their loss reduces Aβ efflux across the BBB[@sagare2013]
Cerebral blood flow dysregulation: Pericytes control capillary diameter via contractile processes; their death causes capillary constriction and chronic hypoperfusion[@hall2014]
Loss of trophic support: Pericytes secrete BDNF, NT-3, and angiopoietin-1, supporting both endothelial and neuronal survival
Cross-links to relevant mechanisms:
Pericyte Dysfunction
Pericyte Loss
Blood-Brain Barrier Breakdown in AD
BBB Dysfunction Pathway
Neurovascular Unit
Neurovascular Unit Dysfunction
Neuroinflammation
Cerebral Small Vessel Disease
Rubric Score
| Dimension | Score | Rationale | |-----------|-------|-----------| | Novelty | 9/10 | No clinical programs target pericyte preservation; PDGFR-β agonism for neuroprotection is entirely unexplored | | Mechanistic Rationale | 8/10 | Pericyte loss clearly precedes and accelerates AD pathology; PDGFR-β is the canonical survival pathway | | Addresses Root Cause | 7/10 | Addresses BBB breakdown (an upstream initiating event) but not protein aggregation directly | | Delivery Feasibility | 6/10 | Paradox: the target is the BBB itself, so circulating biologics have access; but peptides need stabilization for CNS effects | | Safety Plausibility | 6/10 | PDGFR-β stimulation risks fibrosis and smooth muscle proliferation; pericyte-targeted delivery needed for safety | | Combinability | 8/10 | Orthogonal to anti-amyloid, anti-tau, and anti-inflammatory therapies; BBB restoration could improve delivery of all CNS drugs | | Biomarker Availability | 7/10 | CSF sPDGFRβ (soluble receptor shed during pericyte damage) is a validated biomarker of pericyte injury; DCE-MRI measures BBB permeability | | De-risking Path | 7/10 | Pdgfrb-CreERT2 pericyte ablation mice available; PDGFR-β signaling well-characterized; ApoE4 knock-in mice show pericyte loss | | Multi-disease Potential | 8/10 | BBB breakdown documented in AD, PD, ALS, vascular dementia, TBI, MS — pericyte protection relevant across neurology | | Patient Impact | 7/10 | BBB preservation could slow disease progression and improve efficacy of co-administered drugs | | Total | 73/100 | |
De-risking Path
Phase 1 — Peptide engineering: Design stabilized PDGF-BB mimetic peptides with improved PK (PEGylation, cyclization) or small-molecule positive allosteric modulators of PDGFR-β
Phase 2 — Pericyte specificity: Use transferrin receptor-targeted nanoparticles or pericyte-tropic AAV capsids (AAV-BR1) to deliver PDGFR-β agonists selectively to brain pericytes, avoiding systemic fibrotic effects
Phase 3 — Target engagement: Measure CSF sPDGFRβ reduction, DCE-MRI BBB permeability improvement, and pericyte coverage (CD13+/PDGFRβ+ immunofluorescence) in treated versus control mice
Phase 4 — Efficacy models: Test in Pdgfb-ret/ret mice (constitutive pericyte deficiency), ApoE4 knock-in mice (accelerated pericyte loss), and 5xFAD × Pdgfrβ+/- mice (combined BBB + amyloid model)
Phase 5 — Clinical biomarker trial: Enrich for patients with high CSF sPDGFRβ (pericyte damage) and elevated DCE-MRI Ktrans (BBB leak); measure BBB restoration as primary endpoint
Disease Coverage
| Disease | Relevance | Rationale | |---------|-----------|-----------| | Alzheimer's Disease | High | Pericyte loss is one of the earliest detectable changes; BBB breakdown accelerates Aβ accumulation[@sweeney2018] | | Vascular Dementia | High | Small vessel disease and BBB breakdown are the primary pathologies | | Cerebral Small Vessel Disease | High | Pericyte dysfunction drives white matter lesions and lacunar infarcts | | Parkinson's Disease | Medium | BBB disruption in substantia nigra documented; contributes to neuroinflammation | | ALS | Medium | Blood-spinal cord barrier breakdown documented in ALS patients and SOD1 mice[@winkler2013] | | Traumatic Brain Injury | Medium | Acute pericyte loss contributes to secondary injury |
Combination Therapy Potential
With anti-amyloid antibodies (lecanemab/donanemab): BBB restoration could improve antibody brain penetration while reducing ARIA risk from leaky vasculature
With anti-inflammatory approaches: Pericyte restoration blocks peripheral immune cell infiltration, reducing the inflammatory burden that anti-inflammatory drugs must counteract
With cerebral blood flow enhancers: Restored pericyte contractility + vasodilators could synergistically improve cerebral perfusion
Related NeuroWiki Pages
Pericytes | Pericyte Dysfunction | Pericyte Loss
PDGFR-β Protein | PDGFRB Gene
BBB Breakdown in AD | BBB Dysfunction Pathway
Neurovascular Unit | NVU Dysfunction
[Neurovascular Unit Cells](/cell-types/neurovascular-unit-cells)
[Cerebral Small Vessel Disease](/mechanisms/cerebral-small-vessel-disease)
PDGFR-β agonist screening: Test known PDGFR agonists (PDGF-BB, sildenafil derivatives, novel small molecules) in pericyte cultures. Measure pericyte coverage, migration, and BBB tightening function.
In vitro BBB model: Test lead agonists in brain endothelial-pericyte co-culture BBB model. Measure transendothelial electrical resistance (TEER) and permeability of fluorescent tracers.
Pericyte-neuron cross-talk: Co-culture pericytes with iPSC-derived neurons to assess neuroprotective paracrine signaling (BDNF, GDNF release).
Preclinical Development
Lead optimization: Focus on brain-penetrant PDGFR-β selective agonists (avoid off-target VEGFR effects)
Efficacy in vivo: Test in aged mice or AD model (5xFAD) mice with in vivo two-photon imaging of cerebral blood flow
Clinical Path
Indication: Vascular contributions to cognitive impairment and dementia (VCID)
Biomarker development: Use dynamic contrast-enhanced MRI (DCE-MRI) for BBB permeability as endpoint
Funding Strategy
Grant target: NIH R01 (NIA) - Vascular dysfunction in AD
Industry partnership: Partner with vascular biology companies or re-purpose from wound healing
University of Pennsylvania — Dr. John Trojanowski (AD therapeutics)
Stanford University — Dr. Marion Buckwalter (neuroinflammation)
UCLA — Dr. Varghese John (AD clinical trials)
University of Michigan — Dr. Henry Paulsen (biology)
Karolinska Institutet — Dr. Tomas M barek (mechanisms)
Potential Industry Partners
Biogen — Neuroscience pipeline
Roche — CNS portfolio
Merck — Neuroscience division
Takeda — Neuroscience acquisitions
AbbVie — CNS programs
Risk Assessment
| Risk | Likelihood | Impact | Mitigation | |------|------------|--------|------------| | Brain penetration failure | Medium | High | Early PK/PD screening | | Off-target effects | Low | Medium | Selectivity profiling | | Clinical trial recruitment | Low | Medium | Multi-center design |
Regulatory Strategy
Fast Track Designation: Possible
Biomarker Development: Relevant biomarkers
Accelerated Approval: Possible with biomarker endpoint
References
[Sweeney MD, Sagare AP, Zlokovic BV, Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders (2018)](https://pubmed.ncbi.nlm.nih.gov/29129785/))
[Bell RD, Winkler EA, Sagare AP, et al, Pericytes control key neurovascular functions and neuronal phenotype in the adult brain and during brain aging (2010)](https://pubmed.ncbi.nlm.nih.gov/21045130/))
[Ryu JK, Petersen MA, Murray SG, et al, Blood coagulation protein fibrinogen promotes autoimmunity and demyelination via chemokine release and antigen presentation (2015)](https://pubmed.ncbi.nlm.nih.gov/26460133/))
[Sagare AP, Bell RD, Zhao Z, et al, Pericyte loss influences Alzheimer-like neurodegeneration in mice (2013)](https://pubmed.ncbi.nlm.nih.gov/23564631/))
[Hall CN, Reynell C, Gesslein B, et al, Capillary pericytes regulate cerebral blood flow in health and disease (2014)](https://pubmed.ncbi.nlm.nih.gov/24694381/))
[Winkler EA, Sengillo JD, Sullivan JS, Henkel JS, Bhatt P, Bhatt I, Zlokovic BV, Blood-spinal cord barrier breakdown and pericyte reductions in amyotrophic lateral sclerosis (2013)](https://pubmed.ncbi.nlm.nih.gov/23152885/))
[Armulik A, Genové G, Mäe M, et al, Pericytes regulate the blood-brain barrier (2010)](https://pubmed.ncbi.nlm.nih.gov/20966214/))
[Montagne A, Barnes SR, Sweeney MD, et al, Blood-brain barrier breakdown in the aging human hippocampus (2015)](https://pubmed.ncbi.nlm.nih.gov/25586468/))
[Nation DA, Sweeney MD, Montagne A, et al, Blood-brain barrier breakdown is an early biomarker of human cognitive dysfunction (2019)](https://pubmed.ncbi.nlm.nih.gov/30643228/))
[Nikolakopoulou AM, Montagne A, Kisler K, et al, Pericyte loss leads to circulatory failure and pleiotrophin depletion causing neuron loss (2019)](https://pubmed.ncbi.nlm.nih.gov/30742113/))